Torrent Pharma Gets Zero USFDA Observations for Bileshwarpura Oncology Facility
New Delhi: Torrent Pharmaceuticals Limited has successfully completed a USFDA inspection at its Bileshwarpura oncology manufacturing facility with zero observations, indicating full compliance with regulatory standards during the inspection conducted from April 6 to April 10, 2026.
The inspection was carried out by the United States Food and Drug Administration (USFDA) at the company’s oncology-focused plant located in Bileshwarpura. The regulatory review concluded without any Form 483 observations, reflecting adherence to quality and manufacturing norms.
The company disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing stock exchanges about the outcome of the inspection.
A zero-observation outcome is considered a positive regulatory milestone for pharmaceutical manufacturers, as it demonstrates strong compliance with current Good Manufacturing Practices (cGMP) and strengthens the company’s standing in regulated markets such as the United States.
The Bileshwarpura facility plays a key role in Torrent Pharma’s oncology portfolio, and the successful inspection is expected to support its ongoing and future business operations in global markets.
Also Read: Torrent Pharma Plans Rs 12,500 Cr Fund Raise Through Secured NCD Issue
